Compare PLG & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLG | IRWD |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.1M | 251.8M |
| IPO Year | N/A | 2010 |
| Metric | PLG | IRWD |
|---|---|---|
| Price | $2.75 | $3.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.34 |
| AVG Volume (30 Days) | ★ 3.5M | 2.5M |
| Earning Date | 01-13-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | N/A | ★ $338,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.01 |
| P/E Ratio | ★ N/A | $17.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $0.53 |
| 52 Week High | $3.36 | $5.13 |
| Indicator | PLG | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 61.26 | 50.46 |
| Support Level | $2.45 | $3.50 |
| Resistance Level | $2.95 | $3.84 |
| Average True Range (ATR) | 0.22 | 0.27 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 67.52 | 20.78 |
Platinum Group Metals Ltd is the operator of the Waterberg Project, a bulk underground PGM deposit located in South Africa. Waterberg was discovered by Platinum Group and is being jointly developed with Implats, the Japan Oil, Gas and Metals National Corporation (JOGMEC) and Hanwa Co. Ltd. Waterberg has the potential to be a large-scale, low-cost producer of palladium, platinum, rhodium, and gold. Geographically, it operates in Canada and South Africa.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.